Skyler Stein leads Gladskin USA, a biotechnology-driven skincare brand. Gladskin is a leader in global endolysin technology and uses its science to improve inflammatory skin conditions by rebalancing the skin microbiome.

Throughout his career, Skyler has advised, invested in and developed businesses across technology-driven sectors. Most recently, at Obvious Ventures, a venture capital firm dedicated to startups that combine profit and purpose, Skyler focused on companies commercializing microbiome science to improve human health. While seeking investment opportunities in microbiome focused companies, Skyler met the European-based Gladskin team. Gladskin's endolysin technology developed by Micreos B.V. was the most impressive applied science in the space. This inspired Skyler to join the team to further build on Gladskin’s success in Europe and to make the products available to the millions of Americans with inflammatory skin conditions.

Previously, Skyler was a Principal at Bregal Investments, a global private equity firm where he was on the board of various high growth portfolio companies. Skyler has served as an Advisor to Clarity Genomics, which develops computational platforms to elucidate mechanisms of action for human - microbiome interactions.

Skyler holds an M.B.A. from Harvard Business School and a B.A. from Duke University.